Australia's most trusted
source of pharma news
Posted 27 January 2022 AM
Sanofi was among a few companies that slipped through new indications for their therapies before the end of 2021, again pushing forward its PD-1 inhibitor Libtayo.
A TGA update detailing new or extended uses registered in December reveals it took only 43 working days to provisionally approve Libtayo for treatment of adults with a type of skin cancer called metastatic basal cell carcinoma (BCC) while it granted full registration for patients with locally advanced disease.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.